Lung Cancer
Clinical Trial

ImmunityBio is currently conducting a U.S. trial for Lung Cancer:

This is a Phase 3, open-label, 3-cohort, randomized study to compare the safety and efficacy of N-803 (Anktiva) in combination with the current standard of care (experimental arms) versus standard of care alone (control arms), as first-line treatment for subjects with stage 3 or 4 advanced or metastatic NSCLC.

Lean More

ImmunityBio is enrolling healthy volunteers into two clinical trials

BrinkBiologics Logo

ImmunityBio is currently conducting a U.S. trial for Lung Cancer:

Select Eligibility Criteria:

Eligible subjects for this trial must have confirmation that the following mutations are not present: EGFR, ALK Translocation, BRAF, ROS1, and NTRK. Subjects previously treated for Stage 1 or 2 NSCLC are eligible and subjects previously treated for Stage 3 NSCLC who have progressed may still be eligible. You can review a list of all eligibility criteria at ClinicalTrials.gov (link below).

QUILT 2.023 – A Study of N-803 (Anktiva) in Combination with Current Standard of Care vs. Standard of Care as First-Line Treatment for Patients with Stage 3 or 4 Non-Small Cell Lung Cancer (NSCLC)

See if You Qualify

HubSpot form here
 

ImmunityBio is continuously pursuing new immunotherapies designed to attack disease by enhancing the patient’s immune system, not weakening it.